Open original FDA record ↗Recall record
- FDA identifier
- Z-0513-2021
- Company in FDA record
- Biomeme, Inc.
- FDA record creation date
- Dec 1, 2020
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The firm has become aware of nine reports by a single customer that the software made false positive calls. The investigation determined that the root cause is the higher than expected amber-to-red co-excitation in the assay.
Source facts
- Action
- On 10/23/2020, the firm pushed the protocol update and the customer who initiated the complaint was notified. All other customers were informed of the update via email on 10/27/2020. Customers were told that the firm had deployed a change to their data processing algorithm specific to the SARS-CoV-2 protocol, which comprised of increasing the value of the co-excitation filter. Instruction to Customers: If your phone is not connected to the internet via wifi or cellular network, please connect the phone and login to the Biomeme Go app. The update will sync automatically to the Biomeme Go app and requires no further action if the phone running the Biomeme Go app is connected to wifi or a cellular network. The Before Fix Revision is 2020-03-24. The After Fix Revision is 2020-10-23. The firm also emphasized the importance to manually reviewing all results in the app or on the Biomeme Cloud. Should your PCR curves look at all suspect, contact the firm at support@biomeme.com. All positive samples should be rerun.
- Initiated
- 2020-10-23
- Root cause
- Software design
- Terminated
- 2021-01-25
- Distribution
- Worldwide distribution - US Nationwide distribution including in the states of CA, IN, NY, OH, PA, and the countries of Canada, Singapore, Zimbabwe, and Dominican Republic.
- Recall number
- Z-0513-2021
- Recall status
- Terminated
- CDRH record ID
- 184462
- FDA record created
- 2020-12-01
- Recall event number
- 86757